Vir Biotechnology stockholders elect directors, approve executive pay, ratify auditor at 2025 annual meeting

Vir Biotechnology, Inc.

Jeffrey S. Hatfield and Saira Ramasastry elected as Class III directors each with >93 million votes for.
Advisory vote on executive compensation approved: 100.5 million for, 4.3 million against.
Ernst & Young LLP ratified as independent auditor for FY 2025 (116.3 million for).
All three proposals passed; no material change in governance or operations.

item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.